Brazil Vaccine Market

Brazil Vaccine Market Insights Forecasts to 2035

• The Brazil Vaccine Market Size Was Estimated at USD 1.32 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of Around 6.2% from 2025 to 2035
• The Brazil Vaccine Market Size is Expected to Reach USD 2.56 Billion by 2035

According to a research report published by Decision Advisors, The Brazil Vaccine Market Size is anticipated to reach USD 2.56 Billion by 2035, Growing at a CAGR of 6.2% from 2025 to 2035. Rising number of government-led vaccination programs, burgeoning population, the continuous need for immunization boosters, surging public-private collaborations, increasing healthcare services, and a well-established pharmaceutical industry are some of the key factors contributing to the market's positive trajectory.

Market Overview

A vaccine is a biological substance designed to stimulate the body's immune response against one or more specific diseases. It trains the immune system to recognize and combat pathogens, such as viruses or bacteria, by introducing harmless components or inactivated forms of the pathogen. This helps prevent future infections and supports public health through immunization. Additionally, the vaccine market is growing because more people understand how important vaccines are for staying healthy. New scientific advances are helping create better and safer vaccines. Governments also play a big role; they support research, run free vaccination drives, and make sure vaccines reach everyone. These efforts together help protect communities and prevent the spread of serious diseases. Furthermore, one of the major trends in the Brazilian vaccine market is the increasing demand for combination vaccines, which offer protection against multiple diseases in a single shot. This is particularly important in Brazil, where there is a high incidence of diseases such as measles, mumps, and rubella. Another trend is the growing popularity of adult vaccines, particularly for diseases such as influenza and pneumococcal disease.

Report Coverage

This research report categorizes the market for the Brazil vaccine market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Brazil vaccine market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Brazil vaccine market.

Driving Factors

The Brazil vaccine market is driven by increasing public awareness about immunization, government-led initiatives like the National Immunization Program (PNI), and expanding healthcare investments. Local manufacturing by major institutes such as Fiocruz and Butantan ensures a steady supply and innovation. Additionally, advancements in biotechnology, strong R&D support, and collaborations with global health organizations contribute to improving vaccine access, quality, and overall market growth across the country.

Restraining Factors

The Brazil vaccine market faces challenges such as high production costs, strict regulatory approvals, and limited cold chain infrastructure. Vaccine hesitancy, misinformation, and unequal access in rural areas also hinder immunization efforts. Additionally, dependence on imported raw materials and insufficient local R&D capabilities restricts overall market growth and innovation.

Market Segmentation

The Brazil vaccine market share is categorized by product type, route of administration, and distribution channel.

• The multivalent vaccines segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The Brazil vaccine market is segmented by product type into multivalent vaccines and monovalent vaccines. Among these, the multivalent vaccines segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The multivalent vaccines segment holds the largest share in Brazil due to its ability to protect against several diseases with a single dose, making vaccination more efficient and cost-effective. This reduces the number of visits required for immunization, improving patient compliance and coverage rates. Brazil’s strong government initiatives, such as the National Immunization Program (PNI), actively promote multivalent vaccines to enhance accessibility and public health outcomes. Additionally, advancements in biotechnology, improved formulation techniques, and growing partnerships with local producers like the Butantan Institute and Fiocruz support large-scale production and supply. These factors together make multivalent vaccines the most preferred and widely distributed in Brazil’s vaccine market.

• The intramuscular segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The Brazil vaccine market is segmented by route of administration into intramuscular, subcutaneous administration, oral administration, and others. Among these, the intramuscular segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The intramuscular segment dominates due to its high effectiveness, safety, and wide applicability. Intramuscular injections deliver vaccines deep into the muscle tissue, allowing for better absorption and a stronger immune response. Most vaccines used in Brazil’s immunization programs, including those for influenza, hepatitis, HPV, and COVID-19, are administered this way. The method is easy for healthcare professionals to perform, causes fewer local reactions than other routes, and ensures consistent results. Additionally, Brazil’s national immunization guidelines and training programs strongly support intramuscular administration, making it the preferred and most trusted method for large-scale vaccination campaigns.

• The hospital pharmacies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The Brazil vaccine market is segmented by distribution channel into hospital pharmacies, retail pharmacies, institutional sales, and others. Among these, the hospital pharmacies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The hospital pharmacies segment is faster growing due to most vaccination programs are conducted through hospitals, public health centers, and government-supported facilities. Hospitals ensure proper storage, handling, and administration of vaccines under controlled conditions. Additionally, large-scale immunization campaigns and partnerships between hospitals and government agencies make hospital pharmacies the primary channel for vaccine distribution across Brazil.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Brazil vaccine market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Instituto Butantan
• Fundação Oswaldo Cruz (Fiocruz)
• Eurofarma Laboratórios S.A.
• GlaxoSmithKline (GSK)
• Pfizer Inc.
• Merck & Co., Inc.
• AstraZeneca plc
• Sanofi S.A.
• Moderna Inc.
• Other

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In May 2025, Brazil and Gavi, the Vaccine Alliance, signed a revised agreement to boost local vaccine production, expand access to vaccines for climate-sensitive diseases like dengue and yellow fever, and deepen health collaboration with African and Latin American countries. This move strengthens Brazil’s vaccine market by enhancing self-reliance and regional influence, following nearly 20 years of cooperation reaffirmed during the 78th World Health Assembly.
• In April 2025, Brazil’s ANVISA approved Valneva’s single-dose chikungunya vaccine, IXCHIQ, marking the first authorization in an endemic country. The move strengthens Brazil’s public health readiness and supports Phase 4 trials locally. Backed by CEPI, the EU, and Instituto Butantan, the approval highlights Brazil’s growing role in vaccine innovation and access for low- and middle-income countries.

Market Segment

This study forecasts revenue at the Brazil, regional, and country levels from 2020 to 2035. Decision Advisors has segmented the Brazil vaccine market based on the below-mentioned segments:

Brazil Vaccine Market, By Product Type

• Multivalent Vaccine
• Monovalent Vaccine

Brazil Vaccine Market, By Route of Administration

• Intramuscular
• Subcutaneous Administration
• Oral Administration
• Others

Brazil Vaccine Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others